Selected research
Industry Research
Diuretic Drugs Industry Research Report 2026
Market perspective
The global Diuretic Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Diuretic Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Diuretic Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Diuretic Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Diuretic Drugs include Aurobindo Pharma, Bristol-Myers Squibb Compan, F.Hoffmann-La Roche, Fresenius Kabi, Glaxosmithkline, GSK plc, Hikma Pharmaceuticals PLC, Meda Pharmaceuticals and Novartis Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Diuretic Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Diuretic Drugs Market by Company
Aurobindo Pharma
Bristol-Myers Squibb Compan
F.Hoffmann-La Roche
Fresenius Kabi
Glaxosmithkline
GSK plc
Hikma Pharmaceuticals PLC
Meda Pharmaceuticals
Novartis Pharmaceuticals
Teva Pharmaceutical lndustries
yCipla
AstraZeneca
Bayer
Pfizer
Roche
Mylan
Sanofi
Diuretic Drugs Segment by Type
Potassium-sparing Diuretics
Loop Diuretics
Thiazide Diuretics
Osmotic Diuretics
Carbonic Anhydrase Inhibitors
Diuretic Drugs Segment by Application
Online Pharmacies
Hospital Pharmacies
Retail Pharmacies
Diuretic Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diuretic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Diuretic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diuretic Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Diuretic Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Diuretic Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Diuretic Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Potassium-sparing Diuretics
- Loop Diuretics
- Thiazide Diuretics
- Osmotic Diuretics
- Carbonic Anhydrase Inhibitors
Applications
- Online Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
Companies covered
- Aurobindo Pharma
- Bristol-Myers Squibb Compan
- F.Hoffmann-La Roche
- Fresenius Kabi
- Glaxosmithkline
- GSK plc
- Hikma Pharmaceuticals PLC
- Meda Pharmaceuticals
- Novartis Pharmaceuticals
- Teva Pharmaceutical lndustries
- yCipla
- AstraZeneca
- Bayer
- Pfizer
- Roche
- Mylan
- Sanofi
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Diuretic Drugs Market Size (2021-2032)
- 2.2.2 Global Diuretic Drugs Sales (2021-2032)
- 2.2.3 Global Diuretic Drugs Market Average Price (2021-2032)
- 2.3 Diuretic Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Potassium-sparing Diuretics
- 2.3.3 Loop Diuretics
- 2.3.4 Thiazide Diuretics
- 2.3.5 Osmotic Diuretics
- 2.3.6 Carbonic Anhydrase Inhibitors
- 2.4 Diuretic Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Online Pharmacies
- 2.4.3 Hospital Pharmacies
- 2.4.4 Retail Pharmacies
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Diuretic Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Diuretic Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Diuretic Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Diuretic Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Diuretic Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Diuretic Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Diuretic Drugs, Product Type & Application
- 3.8 Global Manufacturers of Diuretic Drugs, Established Date
- 3.9 Global Diuretic Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Aurobindo Pharma
- 4.1.1 Aurobindo Pharma Company Information
- 4.1.2 Aurobindo Pharma Business Overview
- 4.1.3 Aurobindo Pharma Diuretic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Aurobindo Pharma Diuretic Drugs Product Portfolio
- 4.1.5 Aurobindo Pharma Recent Developments
- 4.2 Bristol-Myers Squibb Compan
- 4.2.1 Bristol-Myers Squibb Compan Company Information
- 4.2.2 Bristol-Myers Squibb Compan Business Overview
- 4.2.3 Bristol-Myers Squibb Compan Diuretic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Bristol-Myers Squibb Compan Diuretic Drugs Product Portfolio
- 4.2.5 Bristol-Myers Squibb Compan Recent Developments
- 4.3 F.Hoffmann-La Roche
- 4.3.1 F.Hoffmann-La Roche Company Information
- 4.3.2 F.Hoffmann-La Roche Business Overview
- 4.3.3 F.Hoffmann-La Roche Diuretic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 F.Hoffmann-La Roche Diuretic Drugs Product Portfolio
- 4.3.5 F.Hoffmann-La Roche Recent Developments
- 4.4 Fresenius Kabi
- 4.4.1 Fresenius Kabi Company Information
- 4.4.2 Fresenius Kabi Business Overview
- 4.4.3 Fresenius Kabi Diuretic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Fresenius Kabi Diuretic Drugs Product Portfolio
- 4.4.5 Fresenius Kabi Recent Developments
- 4.5 Glaxosmithkline
- 4.5.1 Glaxosmithkline Company Information
- 4.5.2 Glaxosmithkline Business Overview
- 4.5.3 Glaxosmithkline Diuretic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Glaxosmithkline Diuretic Drugs Product Portfolio
- 4.5.5 Glaxosmithkline Recent Developments
- 4.6 GSK plc
- 4.6.1 GSK plc Company Information
- 4.6.2 GSK plc Business Overview
- 4.6.3 GSK plc Diuretic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 GSK plc Diuretic Drugs Product Portfolio
- 4.6.5 GSK plc Recent Developments
- 4.7 Hikma Pharmaceuticals PLC
- 4.7.1 Hikma Pharmaceuticals PLC Company Information
- 4.7.2 Hikma Pharmaceuticals PLC Business Overview
- 4.7.3 Hikma Pharmaceuticals PLC Diuretic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Hikma Pharmaceuticals PLC Diuretic Drugs Product Portfolio
- 4.7.5 Hikma Pharmaceuticals PLC Recent Developments
- 4.8 Meda Pharmaceuticals
- 4.8.1 Meda Pharmaceuticals Company Information
- 4.8.2 Meda Pharmaceuticals Business Overview
- 4.8.3 Meda Pharmaceuticals Diuretic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Meda Pharmaceuticals Diuretic Drugs Product Portfolio
- 4.8.5 Meda Pharmaceuticals Recent Developments
- 4.9 Novartis Pharmaceuticals
- 4.9.1 Novartis Pharmaceuticals Company Information
- 4.9.2 Novartis Pharmaceuticals Business Overview
- 4.9.3 Novartis Pharmaceuticals Diuretic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Novartis Pharmaceuticals Diuretic Drugs Product Portfolio
- 4.9.5 Novartis Pharmaceuticals Recent Developments
- 4.10 Teva Pharmaceutical lndustries
- 4.10.1 Teva Pharmaceutical lndustries Company Information
- 4.10.2 Teva Pharmaceutical lndustries Business Overview
- 4.10.3 Teva Pharmaceutical lndustries Diuretic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Teva Pharmaceutical lndustries Diuretic Drugs Product Portfolio
- 4.10.5 Teva Pharmaceutical lndustries Recent Developments
- 4.11 yCipla
- 4.11.1 yCipla Company Information
- 4.11.2 yCipla Business Overview
- 4.11.3 yCipla Diuretic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 yCipla Diuretic Drugs Product Portfolio
- 4.11.5 yCipla Recent Developments
- 4.12 AstraZeneca
- 4.12.1 AstraZeneca Company Information
- 4.12.2 AstraZeneca Business Overview
- 4.12.3 AstraZeneca Diuretic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 AstraZeneca Diuretic Drugs Product Portfolio
- 4.12.5 AstraZeneca Recent Developments
- 4.13 Bayer
- 4.13.1 Bayer Company Information
- 4.13.2 Bayer Business Overview
- 4.13.3 Bayer Diuretic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Bayer Diuretic Drugs Product Portfolio
- 4.13.5 Bayer Recent Developments
- 4.14 Pfizer
- 4.14.1 Pfizer Company Information
- 4.14.2 Pfizer Business Overview
- 4.14.3 Pfizer Diuretic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Pfizer Diuretic Drugs Product Portfolio
- 4.14.5 Pfizer Recent Developments
- 4.15 Roche
- 4.15.1 Roche Company Information
- 4.15.2 Roche Business Overview
- 4.15.3 Roche Diuretic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Roche Diuretic Drugs Product Portfolio
- 4.15.5 Roche Recent Developments
- 4.16 Mylan
- 4.16.1 Mylan Company Information
- 4.16.2 Mylan Business Overview
- 4.16.3 Mylan Diuretic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Mylan Diuretic Drugs Product Portfolio
- 4.16.5 Mylan Recent Developments
- 4.17 Sanofi
- 4.17.1 Sanofi Company Information
- 4.17.2 Sanofi Business Overview
- 4.17.3 Sanofi Diuretic Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Sanofi Diuretic Drugs Product Portfolio
- 4.17.5 Sanofi Recent Developments
5 Global Diuretic Drugs Market Scenario by Region
- 5.1 Global Diuretic Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Diuretic Drugs Sales by Region: 2021-2032
- 5.2.1 Global Diuretic Drugs Sales by Region: 2021-2026
- 5.2.2 Global Diuretic Drugs Sales by Region: 2027-2032
- 5.3 Global Diuretic Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Diuretic Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Diuretic Drugs Revenue by Region: 2027-2032
- 5.4 North America Diuretic Drugs Market Facts & Figures by Country
- 5.4.1 North America Diuretic Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Diuretic Drugs Sales by Country (2021-2032)
- 5.4.3 North America Diuretic Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Diuretic Drugs Market Facts & Figures by Country
- 5.5.1 Europe Diuretic Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Diuretic Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Diuretic Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Diuretic Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Diuretic Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Diuretic Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Diuretic Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Diuretic Drugs Market Facts & Figures by Country
- 5.7.1 South America Diuretic Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Diuretic Drugs Sales by Country (2021-2032)
- 5.7.3 South America Diuretic Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Diuretic Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Diuretic Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Diuretic Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Diuretic Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Diuretic Drugs Sales by Type (2021-2032)
- 6.1.1 Global Diuretic Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Diuretic Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Diuretic Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Diuretic Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Diuretic Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Diuretic Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Diuretic Drugs Sales by Application (2021-2032)
- 7.1.1 Global Diuretic Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Diuretic Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Diuretic Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Diuretic Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Diuretic Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Diuretic Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Diuretic Drugs Value Chain Analysis
- 8.1.1 Diuretic Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Diuretic Drugs Production Mode & Process
- 8.2 Diuretic Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Diuretic Drugs Distributors
- 8.2.3 Diuretic Drugs Customers
9 Global Diuretic Drugs Analyzing Market Dynamics
- 9.1 Diuretic Drugs Industry Trends
- 9.2 Diuretic Drugs Industry Drivers
- 9.3 Diuretic Drugs Industry Opportunities and Challenges
- 9.4 Diuretic Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst